Evommune, Inc.
EVMN
$24.09
-$0.94-3.76%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Net Income | -36.41% | 21.62% | 50.46% | -422.88% | |
| Total Depreciation and Amortization | -9.44% | -6.04% | 15.38% | 39.11% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 7,422.92% | -36.36% | -14,004.84% | 251.55% | |
| Change in Net Operating Assets | 322.87% | 123.14% | -123.11% | -362.11% | |
| Cash from Operations | 9.79% | 63.26% | -203.83% | -394.80% | |
| Capital Expenditure | -- | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -271.21% | -352.60% | 79.19% | 38.92% | |
| Cash from Investing | -271.53% | -353.99% | 79.52% | 39.93% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | 38.13% | -19.30% | -43.52% | -148.39% | |
| Issuance of Common Stock | 1,429,754.55% | -- | -- | 0.00% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -100.00% | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | 215.58% | -140.35% | 59,675.00% | -153.33% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 1,012.11% | -99.75% | 4,241.30% | -321.75% | |